136518-02-0

Basic information

• Product Name: 4-Pyrimidinecarbonylchloride,6-chloro-2-methyl-(9CI)
• Synonyms: 4-Pyrimidinecarbonylchloride,6-chloro-2-methyl-(9CI);6-Chloro-2-methyl-pyrimidine-4-carbonyl chloride
• CAS NO: 136518-02-0
• Molecular Formula: C6H4Cl2N2O
• Molecular Weight: 191.017
• Product Categories: ACIDHALIDE
• Mol File: 136518-02-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Pyrimidinecarbonylchloride,6-chloro-2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinecarbonylchloride,6-chloro-2-methyl-(9CI)(136518-02-0)
• EPA Substance Registry System: 4-Pyrimidinecarbonylchloride,6-chloro-2-methyl-(9CI)(136518-02-0)

Safety Data

• Hazardous Substances Data: 136518-02-0(Hazardous Substances Data)

Upstream product

• 10026-13-8 phosphorus pentachloride 
• 34415-10-6 6-hydroxy-2-methylpyrimidine-4-carboxylic acid 

Relevant articles and documents

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

SOLUBILIZED THIAZOLOPYRIDINES

Provided herein are novel sirtuin-modulating compounds Structural Formula (I): and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.